CD8A and diffuse large B-cell lymphoma: In multivariate analysis of subsequent OS, low CD4:CD8 ratio (relative risk [RR]: 3.26, 95% CI: 1.06-10.06, p=0.039) remained a significant predictor in PG-DLBCL patients who were newly diagnosed and did not receive rituximab.